The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).
 
Ami N. Shah
No Relationships to Disclose
 
Lisa E. Flaum
Consulting or Advisory Role - Novartis; Puma Biotechnology
Speakers' Bureau - Novartis
 
Alfred Rademaker
Research Funding - Siemens (Inst)
Other Relationship - Georgetown Univ.; JAMA-Journal of the American Medical Association
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Genomic Health; Polyphor
Research Funding - Medimmune; Pfizer; Pfizer; Tesaro (Inst)
 
Sarika Jain
No Relationships to Disclose
 
Irene B. Helenowski
No Relationships to Disclose
 
Kelly Kindy
No Relationships to Disclose
 
Tara Dedic
No Relationships to Disclose
 
Regina Uthe
No Relationships to Disclose
 
Valerie Nelson
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Dean Tsarwhas
No Relationships to Disclose
 
Massimo Cristofanilli
Honoraria - Pfizer
Consulting or Advisory Role - CytoDyn; Merus; Novartis
 
William John Gradishar
Consulting or Advisory Role - Genentech/Roche